| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Common Stock | Sale | $80,164 | -1,884 | -52% | $42.55 | 1,761 | 22 Feb 2022 | Direct | F1 |
| transaction | BSX | Common Stock | Sale | $76,216 | -1,761 | -100% | $43.28 | 0 | 23 Feb 2022 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Performance Share Units | Award | $0 | +17,439 | $0.000000 | 17,439 | 22 Feb 2022 | Common Stock | 17,439 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. |
| F2 | Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| F3 | On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. |